No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PRTA Prothena
- 20.340
- -0.790-3.74%
Trading Jun 10 13:05 ET
1.09BMarket Cap-6336P/E (TTM)
21.095High20.160Low116.72KVolume20.620Open21.130Pre Close2.42MTurnover0.30%Turnover RatioLossP/E (Static)53.77MShares73.13552wk High2.18P/B779.84MFloat Cap19.52052wk Low--Dividend TTM38.34MShs Float79.749Historical High--Div YieldTTM4.43%Amplitude5.640Historical Low20.736Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships
Prothena (PRTA) Receives a Buy From Piper Sandler
Analysts' Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)
Bristol Myers Squibb Adds to Neurodegenerative Treatment Investments -- Market Talk
1851 ET - Bristol Myers Squibb is not done bolstering its neuroscience portfolio after splashing cash last year. Biotechnology company Prothena says Bristol Myers has opted to obtain the exclusive glo
Comments
Investors may miss opportunities or face setbacks if there's no rational basis for the P/S ratio. The moderate P/S ratio suggests investors anticipate a slowdown in revenue. Many investors, less bearish than analysts, hold onto their stocks, risking future disappointment if P/S aligns with growth outlook.
What Prothena Corporation Plc's (NASDAQ:PRTA) P/S Is Not Telling YouAnalysts are forecasting that Prothena will reach break-even point before it might exhaust its cash runway. Given its impressive revenue growth and reduction in cash burn, Prothena appears well positioned to fund further growth with minimal shareholder dilution or borrowing.
Despite recent declines, the company's strong growth signals a potential investment opportunity. Market response to its revenue growth indicates interest despite lack of profits.
Overvaluation risk looms for Prothena's shares with high P/S ratio amid poor revenue and weak growth forecast. Investors may face disappointment if the share price realigns with the firm's bleak future outlook.
$Prothena(PRTA.US$. Up up up
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg